Wealth Enhancement Advisory Services LLC Buys 56,734 Shares of Zoetis Inc. (NYSE:ZTS)

Wealth Enhancement Advisory Services LLC boosted its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 22.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 305,611 shares of the company's stock after acquiring an additional 56,734 shares during the quarter. Wealth Enhancement Advisory Services LLC owned 0.07% of Zoetis worth $49,793,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in ZTS. Atlantic Edge Private Wealth Management LLC lifted its position in Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after buying an additional 140 shares in the last quarter. Rakuten Securities Inc. lifted its position in Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after buying an additional 166 shares in the last quarter. Navigoe LLC bought a new stake in Zoetis during the 4th quarter worth about $30,000. Murphy & Mullick Capital Management Corp bought a new stake in Zoetis during the 4th quarter worth about $44,000. Finally, Asset Planning Inc bought a new stake in Zoetis during the 4th quarter worth about $58,000. 92.80% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. UBS Group dropped their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Stifel Nicolaus decreased their price target on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Piper Sandler upped their price target on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Monday, May 12th. Barclays upped their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Finally, Wall Street Zen upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $212.75.

Insiders Place Their Bets

In other news, Director Willie M. Reed sold 1,210 shares of the firm's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. This trade represents a 2.02% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.18% of the company's stock.

Zoetis Stock Performance

ZTS traded up $1.57 during midday trading on Friday, reaching $168.71. The company had a trading volume of 5,467,815 shares, compared to its average volume of 2,533,285. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The stock has a market cap of $75.11 billion, a PE ratio of 30.84, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33. The business has a 50-day moving average price of $156.80 and a two-hundred day moving average price of $164.59.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The company had revenue of $2.22 billion for the quarter, compared to analysts' expectations of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Zoetis's revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the company posted $1.38 EPS. On average, sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.19%. The ex-dividend date is Friday, July 18th. Zoetis's dividend payout ratio is presently 35.91%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.